Protagonist Therapeutics Inc. Dividend Analysis

No. Protagonist Therapeutics (PTGX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.

It largely does not. Protagonist Therapeutics pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

On the numbers, yes. Protagonist Therapeutics generated $131 million of free cash flow, which is about $1.84 per share. If it paid out half of that, the dividend would be roughly $0.92 per share, a yield of about 0.6% at the current price. That is an illustration of capacity, not a prediction: the company has given no indication it intends to pay one.

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Protagonist Therapeutics.